Your browser doesn't support javascript.
loading
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
Wilson, Edward N; Young, Christina B; Ramos Benitez, Javier; Swarovski, Michelle S; Feinstein, Igor; Vandijck, Manu; Le Guen, Yann; Kasireddy, Nandita M; Shahid, Marian; Corso, Nicole K; Wang, Qian; Kennedy, Gabriel; Trelle, Alexandra N; Lind, Betty; Channappa, Divya; Belnap, Malia; Ramirez, Veronica; Skylar-Scott, Irina; Younes, Kyan; Yutsis, Maya V; Le Bastard, Nathalie; Quinn, Joseph F; van Dyck, Christopher H; Nairn, Angus; Fredericks, Carolyn A; Tian, Lu; Kerchner, Geoffrey A; Montine, Thomas J; Sha, Sharon J; Davidzon, Guido; Henderson, Victor W; Longo, Frank M; Greicius, Michael D; Wagner, Anthony D; Wyss-Coray, Tony; Poston, Kathleen L; Mormino, Elizabeth C; Andreasson, Katrin I.
Afiliação
  • Wilson EN; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA. enwilson@stanford.edu.
  • Young CB; Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA. enwilson@stanford.edu.
  • Ramos Benitez J; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Swarovski MS; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Feinstein I; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Vandijck M; Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, CA, USA.
  • Le Guen Y; Fujirebio Europe NV, Ghent, Belgium.
  • Kasireddy NM; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Shahid M; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Corso NK; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Wang Q; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Kennedy G; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Trelle AN; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Lind B; Psychology, Stanford University, Stanford, CA, USA.
  • Channappa D; Neurology, Portland VA Medical Center, Portland, OR, USA.
  • Belnap M; Neurology, Oregon Health & Science University, Portland, OR, USA.
  • Ramirez V; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Skylar-Scott I; Pathology, Stanford University, Stanford, CA, USA.
  • Younes K; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Yutsis MV; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Le Bastard N; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Quinn JF; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • van Dyck CH; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Nairn A; Fujirebio Europe NV, Ghent, Belgium.
  • Fredericks CA; Neurology, Portland VA Medical Center, Portland, OR, USA.
  • Tian L; Neurology, Oregon Health & Science University, Portland, OR, USA.
  • Kerchner GA; Psychiatry, Yale University, New Haven, CT, USA.
  • Montine TJ; Psychiatry, Yale University, New Haven, CT, USA.
  • Sha SJ; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Davidzon G; Biomedical Data Science, Stanford University, Stanford, CA, USA.
  • Henderson VW; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Longo FM; Pathology, Stanford University, Stanford, CA, USA.
  • Greicius MD; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Wagner AD; Radiology, Stanford University, Stanford, CA, USA.
  • Wyss-Coray T; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
  • Poston KL; Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.
  • Mormino EC; Epidemiology & Population Health, Stanford University, Stanford, CA, USA.
  • Andreasson KI; Neurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Alzheimers Res Ther ; 14(1): 172, 2022 11 12.
Article em En | MEDLINE | ID: mdl-36371232
BACKGROUND: The recent promise of disease-modifying therapies for Alzheimer's disease (AD) has reinforced the need for accurate biomarkers for early disease detection, diagnosis and treatment monitoring. Advances in the development of novel blood-based biomarkers for AD have revealed that plasma levels of tau phosphorylated at various residues are specific and sensitive to AD dementia. However, the currently available tests have shortcomings in access, throughput, and scalability that limit widespread implementation. METHODS: We evaluated the diagnostic and prognostic performance of a high-throughput and fully-automated Lumipulse plasma p-tau181 assay for the detection of AD. Plasma from older clinically unimpaired individuals (CU, n = 463) and patients with mild cognitive impairment (MCI, n = 107) or AD dementia (n = 78) were obtained from the longitudinal Stanford University Alzheimer's Disease Research Center (ADRC) and the Stanford Aging and Memory Study (SAMS) cohorts. We evaluated the discriminative accuracy of plasma p-tau181 for clinical AD diagnosis, association with amyloid ß peptides and p-tau181 concentrations in CSF, association with amyloid positron emission tomography (PET), and ability to predict longitudinal cognitive and functional change. RESULTS: The assay showed robust performance in differentiating AD from control participants (AUC 0.959, CI: 0.912 to 0.990), and was strongly associated with CSF p-tau181, CSF Aß42/Aß40 ratio, and amyloid-PET global SUVRs. Associations between plasma p-tau181 with CSF biomarkers were significant when examined separately in Aß+ and Aß- groups. Plasma p-tau181 significantly increased over time in CU and AD diagnostic groups. After controlling for clinical diagnosis, age, sex, and education, baseline plasma p-tau181 predicted change in MoCA overall and change in CDR Sum of Boxes in the AD group over follow-up of up to 5 years. CONCLUSIONS: This fully-automated and available blood-based biomarker assay therefore may be useful for early detection, diagnosis, prognosis, and treatment monitoring of AD.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva Tipo de estudo: Prognostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article